All News

A new combination was shown to mitigate graft-versus-host disease (GVHD) for patients undergoing a hematopoietic stem cell transplant (HSCT).

The number of positive lymph nodes can help guide treatment for locally advanced head and neck cancer, according to a recent study.

Axicabtagene ciloleucel had high response rates in patients with non-Hodgkin lymphoma in a phase 2 study.

Breast cancer and melanoma survivor vents about her weight gain frustrations several years out from her original cancer diagnosis.

We whisper it. We avoid it. But as scary as open communication is, we must utter that word.

As Ed completes his final chemo cycle, he loses a friend.

"Telenutrition" programs can help high-risk patients who do not otherwise have access to a registered dietician, according to a recent study and program launched at the Carolinas HealthCare System.

Getting dates while getting Adriamycin.

Cabometyx combinations showed activity in patients with GU cancers, according to a preliminary clinical study.

David McDermott, M.D. discusses new advances made to treat kidney cancer.

The FDA granted Zykadia a priority review for the frontline treatment of some patients with lung cancer.

Two-time survivor reflects about the cancer experience and offers perspective and hope.

Since it is found in the majority of patients with mCRPC, circulating tumor DNA may be able to lead the way to more personalized prostate cancer care.

More people with AML who were treated with Vyxeos were moved to transplant than those treated with a standard chemotherapy regimen, according to recent findings.

A phase 2 trial is showing that GPX-150 is promising for patients with soft tissue sarcoma.

Finola Hughes from TV's "General Hospital" and Ellen K. Ritchie, M.D. are teaming up to raise awareness for polycythemia vera.

Patients with metastatic bladder cancer who did not see a benefit on single-agent Opdivo did better when the drug was combined with Yervoy, a recent study showed.

Once the unwanted growth of one’s cancer is addressed, how does one prepare the psychological inner terrain to receive the healing nurturance that carries one from illness to wellness?

The Food and Drug Administration (FDA) approved Revlimid (lenalidomide) for maintenance therapy for some patients with multiple myeloma.

An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open.

A regimen without gemcitabine had promising survival rates for patients with metastatic pancreatic cancer, according to a recent study.

A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.

Inotuzumab ozogamicin was granted a priority review designation for patients with relapsed or refractory ALL.

Your methods of coping with cancer might not always be sexy.

Durvalumab and Lynparza (olaparib) provided a response for patients in a small study.

Checkpoint inhibitors drastically changed the treatment landscape of urothelial carcinoma, and more changes are on the way.

CURE spoke with Eric Smith, M.D., Ph.D. about immunotherapy and other advances being made in multiple myeloma.

Believing and having faith during a seemingly impossible time in life can make all the difference.

One quirky trick to cut down on hair loss from chemo made me detest refrigerators for life!

On Feb. 21, we'll be co-hosting a tweet chat with Oncology Nursing News and Will2Love's Leslie R. Schover about sexual health and fertility after a cancer diagnosis. Join us at 9 p.m. EST with the hashtag #CureConnect